Thats led to another trend that worries health care providers: the growing number of people accessing lower-cost GLP-1s through online compounding pharmacies
Presented at the American Heart Associations 2023 Scientific Sessions (1113 November, Philadelphia, USA), the results of the SELECT trial showed that overweight or obese people without diabetes taking semaglutide for more than three years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight
After 6 weeks, the body is fully adapted and ready for long-term use at 12mg
Duarte C, Pinto-Gouveia J, Ferreira C
Learn more about our medical weight loss program , including semaglutide, tirzepatide, and retatrutide options